Clinical trials: Homologous Recombination Deficiency
Pancreatic Adenocarcinoma, Homologous Recombination Deficiency
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency
The purpose of this study is to evaluate the efficacy of cisplatin based regimen to patients with advanced pancreatic cancer and homologous recombination deficiency.
- Trial name
- PTCA199-6 (NCT06095141)
- Testing
- Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Homologous Recombination Deficient Solid Tumors
Niraparib and Dostarlimab in HRD Solid Tumors
This is an open-label, single-arm, Phase 2 study which will evaluate the efficacy and safety of niraparib and dostarlimab (TSR-042) combination in patients with metastatic, recurrent, or unresectable solid tumor with a…
- Trial name
- DIDO (NCT04983745)
- Testing
- Combination drug
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- West Cancer Center
Triple-Negative Breast Cancer (TNBC)
Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer
This is a single-arm, prospective, Phase II clinical trial designed to assess the efficacy and safety of QL1706 in combination with olaparib in patients with recurrent or metastatic triple-negative breast cancer (TNBC) harboring…
- Trial name
- NCT07005583
- Testing
- QL1706 Plus Olaparib
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Ovarian Cancer
A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer
This study will collect the data from existing patient medical records at US cancer centers. The study will include patients with BRCAwt ovarian cancer who have been prescribed first line (1L) olaparib maintenance treatment.
- Trial name
- FLAME (NCT05775549)
- Testing
- None (Observational Study)
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Ovarian Cancer
Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib
In this study, investigators propose to use fuzuloparib and apatinib as neoadjuvant therapy for Homologous recombination deficiency （HRD）positive advanced ovarian cancer patients, aiming to explore the efficacy and safety of this…
- Trial name
- NCT07033819
- Testing
- Neoadjuvant therapy with fuzuloparib in combination with apatinib, Preoperative Period, Chemotherapy
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Epithelial Ovarian Cancer, Homologous Recombination Deficiency
HRD and Resistance to PAPPi in EOC Patients
The association between homologous recombination (HR) gene mutations and homologous recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients has been investigated in previous studies (NCT04190667…
- Conditions
- Epithelial Ovarian Cancer, Homologous Recombination Deficiency, Homologous Recombination Repair Gene Mutation, Poly(ADP-ribose) Polymerase Inhibitor
- Trial name
- NCT05310370
- Testing
- Testing of homologous recombination deficiency
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Lei Li
Ovarian Neoplasm Epithelial, Homologous Recombination Deficiency
Functional Analysis of BRCAness
PARP inhibitors are most effective in homologous recombinant (HR) deficient tumors. There are clear indications that besides BRCA1 or BRCA2 mutated EOC, there is an additional group of EOC having deficiencies in HR (i.e.
- Conditions
- Ovarian Neoplasm Epithelial, Homologous Recombination Deficiency, BRCA1 Mutation, BRCA2 Mutation
- Trial name
- FAB (NCT04780945)
- Testing
- Functional RAD51 assay, Olaparib Oral Product
- Where
- 3 sites in Netherlands
- Volunteers
- 27 people
- Sponsor
- Leiden University Medical Center
Homologous Recombination Deficiency, Triple Negative Breast Cancer
Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency
The incidence of homologous recombination deficiency in metastatic triple negative breast cancer was 52%-59%，PARP plays a key role in sensing DNA damage and converting it into intracellular signals that activate the base excision…
- Trial name
- NCT05461690
- Testing
- Niraparib
- Volunteers
- 50 people
- Sponsor
- Zhejiang Cancer Hospital
Metastatic Pancreatic Ductal Adenocarcinoma, Homologous Recombination Deficiency (HRD)
A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy
The study researchers think that combining the drugs pembrolizumab and olaparib (POLAR) may help people with this disease because pembrolizumab activates the immune system to fight cancer, and olaparib destroys cancer cells by…
- Trial name
- NCT04666740
- Testing
- Pembrolizumab, Olaparib
- Where
- 7 sites in United States
- Volunteers
- 63 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, HER2-low Breast Cancer
Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer
This is a cross-sectional and an observational study, investigator-initiated study in HER2-low breast cancer patients. Approximately 255 subjects with HRD (homologous recombination deficiency) assessment will be enrolled in this…
- Trial name
- NCT05466786
- Testing
- Standard Management
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Ovarian Cancer, Epithelial Ovarian Cancer
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ARIEL2 (NCT01891344)
- Testing
- Oral rucaparib
- Where
- 75 sites in United States, Australia and 4 more
- Volunteers
- 491 people
- Sponsor
- pharmaand GmbH
MMR-D/MSI-H Colorectal Cancers
Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers
The second line of therapy for patients with MSI-H CRC who experience disease progression on anti-PD1 based therapies is not well defined and there is an unmet need for research for patients with anti-PD1 refractory MSI-H CRC.
- Trial name
- NCT06365970
- Testing
- Niraparib, Dostarlimab
- Sponsor
- Ibrahim Halil Sahin
Ovarian Cancer, HRD
Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients
Homologous recombination deficiency (HRD) is an important molecular biomarker for Poly (ADP-ribose) polymerase inhibitors (PARPi) which is a significant progress in the treatment of ovarian cancer.
- Conditions
- Ovarian Cancer, HRD, PARP Inhibitor
- Trial name
- HOPEI (NCT05044091)
- Testing
- PARP inhibitor
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xiaoxiang Chen
Advanced Solid Tumor, Metastatic Solid Tumor
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
This is an open-label, multicenter, phase 2 study of lurbinectedin monotherapy in participants with advanced (metastatic and/or unresectable) solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Urothelial Cancer, Poorly Differentiated Neuroendocrine Carcinomas
- Trial name
- JAZZ EMERGE201 (NCT05126433)
- Testing
- Lurbinectedin
- Where
- 17 sites in United States
- Volunteers
- 47 people
- Sponsor
- Jazz Pharmaceuticals
Solid Tumors
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable)…
- Trial name
- NCT04123366
- Testing
- Olaparib, Pembrolizumab
- Where
- 135 sites in United States, Argentina and 21 more
- Volunteers
- 333 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer.
- Conditions
- Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations
- Trial name
- COBRA (NCT04038502)
- Testing
- Carboplatin, Olaparib
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- VA Office of Research and Development
Ovarian Cancer, Fallopian Tube Cancers
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
- Trial name
- NCT07472140
- Testing
- PARP inhibitor + Bevacizumab, PARP inhibitor
- Where
- Belarus
- Volunteers
- 120 people
- Sponsor
- N.N. Alexandrov National Cancer Centre
Solid Tumor, Adult
Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors
Phase II trial in which patients with metastatic solid tumors experiencing progression after first line standard chemotherapy or for which there is no standard chemotherapy, and for which pembrolizumab does not have an FDA or…
- Trial name
- NCT03274661
- Testing
- Pembrolizumab 200 mg Q3W
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Baptist Health South Florida
Metastatic Castration-Resistant Prostate Cancer
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer…
- Trial name
- NCT05005728
- Testing
- vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy
- Where
- 26 sites in United States
- Volunteers
- 72 people
- Sponsor
- Xencor, Inc.
Triple Negative Breast Cancer
The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency
The purpose of this trial is to compare the 3-year disease-free survival of dose-dense epirubicin and cyclophosphamide followed by paclitaxel with paclitaxel plus carboplatin as adjuvant therapy for triple-negative breast cancer…
- Trial name
- NCT03876886
- Testing
- Epirubicin, Cyclophosphamide, Paclitaxel
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese Academy of Medical Sciences